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Abstract The human ll-opioid receptor cDNA from which the 
32 amino-terminal codons were substituted by the Saccharo- 
myces cerevisiae a-mating factor signal sequence has been 
expressed in the methylotrophic yeast Pichia pastoris using the 
host promoter of the alcohol oxidase-1 gene. Cell membranes 
exhibited specific and saturable binding of the opioid antagonist 
[3H]diprenorphine (Kd = 0.2 nM and Bma x = 400 fmol/mg protein 
or 800 sites/cell). Competition studies with non-selective, and I ~-, 
fi- and ~-selective opioid agonists and antagonists revealed a 
typical l.t-opioid receptor binding profile, suggesting proper 
folding of the protein in yeast membranes. 
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I. Introduction 
Many compounds of the modern pharmacopoeia exert their 
effects by binding to G-protein-coupled receptors which share 
many structural features including seven a-helical membrane- 
spanning domains. Among these, opioid receptors are of par- 
ticular importance since they represent the target of the most 
potent and as yet unequalled central analgesics. G-protein- 
coupled receptors are perhaps the most widespread pharma- 
cological targets, and thus there is great interest in obtaining 
structural data that could provide new leads and concepts 
during the research and development of selective therapeutic 
agents. 
During the past decade, hundreds of genes coding for G- 
protein-coupled receptors have been isolated. Biochemical nd 
mutagenesis experiments have allowed accumulation of a 
wealth of information on the structure/function relationships 
within this family of receptors. However, interpretation f the 
data relies on substantially speculative three-dimensional 
models derived from the structure of related but yet poorly 
homologous molecules uch as bacterial and visual opsins [1- 
3]. Indeed, G-protein-coupled receptors generally occur at 
very low levels in biological materials and direct structural 
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Abbreviations: HUMOR, human ~t-opioid receptor; AOX1, gene for 
alcohol oxidase-1; STE2, gene for a-mating factor receptor; MD, 
minimal dextrose; MM, minimal methanol; BMGY, buffered minimal 
glycerol-complex medium; BMMY, buffered minimal methanol- 
complex medium; PMSF, phenylmethylsulfonyl fluoride; 5-HT, 5- 
hydroxytryptamine; DPN, diprenorphine; DAGO, [D-AIa2,N-Me - 
Phe4,Gly-olS]enkephalin; DTLET, Tyr-D-Thr-Gly-Phe-Leu-Thr; U- 
50,488, trans-(- )-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclo- 
hexyl]benzene acetamide; [3-FNA, 13-funaltrexamine; ICI-174,846, 
N,N-diallyl-Tyr-Aib-Aib-Phe-Leu; NorBNI, nor-binaltorphimine 
studies such as neutron or electron diffraction, NMR spec- 
troscopy and X-ray crystallography cannot yet be performed. 
The methylotrophic yeast, Pichia pastoris has been de- 
scribed as a particularly efficient host for high level expression 
of heterologous genes when these are placed under control of 
the host alcohol oxidase-1 (AOX1) promoter [4]. The activity 
of the AOX1 promoter is tightly regulated. It is repressed in 
the presence of glucose or glycerol, allowing production of 
more than 100 g of dry cell weight/1 [5]. In the presence of 
methanol, promoter activity is maximal and AOX1 may then 
contribute to 30% of the total protein content [6]. Produced 
proteins are usually properly folded because P. pastoris pro- 
vides an intracellular folding machinery similar to that of 
mammalian cells. Finally, P. pastoris can be grown in minimal 
medium to obtain 2H-, 15N- and laC-labelled proteins [7]. 
This system has been used for heterologous expression of 
secreted or intracellular p oteins [8] but there is a single report 
on the expression of a G-protein-coupled receptor, the 5- 
HTsA serotonin receptor, in P. pastoris with expression levels 
as high as 20 pmol/mg membrane protein [9]. Moreover, de- 
spite the cloning of numerous genes for G-protein-coupled 
receptors, only five of these have been expressed in yeast [9- 
15]. In this paper, we report on the expression of the human 
g-opioid receptor (HUMOR) in the methylotrophic yeast P. 
pastoris. The typical a-opioid binding profile of the expressed 
protein suggests that it is folded in the yeast membrane in a 
conformation close to that occurring in mammalian cells. 
2. Materials and methods 
2.1. Vector construction 
The cDNA for the HUMOR was isolated by reverse transcription 
and PCR-amplification from human euroblastoma SH-SY-5Y RNA 
(Emorine, L.J., unpublished). The coding region of the cDNA was 
cloned into the pGEM4z vector, yielding the pGEM4z-HuMOR con- 
struct. The sequence of the eDNA was shown to be identical to that 
already published [16]. 
Two expression vectors were constructed using the commercially 
available (Invitrogen, San Diego, USA) P. pastoris expression vector 
pPIC9 (Fig. 1). For one construct, a synthetic oligonucleotide consti- 
tuted of 25 bp of 5' non-coding sequences containing a BglII site and 
a yeast ranslation initiation codon, and of 55 bp coding for the 
amino-terminal part of the Saccharomyces cerevisiae STE2 gene [17] 
was inserted into the SacI and MunI sites of pGEM4z-HuMOR. This 
resulted in the replacement of the 11 amino-terminal codons of the 
HUMOR cDNA by the 18 amino-terminal codons of the STE2 gene. 
A BglII to XbaI fragment was purified from the resulting plasmid and 
cloned into the BamHI and AvrII sites of pPIC9 to yield pPIC9-STE2- 
HUMOR (Fig. 1A). For the second construct, pPIC9-aMF-HuMOR, 
a HinclI to EeoRI fragment was purified from pGEM4z-HuMOR and 
ligated into the SnaBI and EcoRI sites of pPIC9 (Fig. 1B). This 
resulted in the replacement of the 32 amino-terminal codons of the 
HUMOR cDNA by the S. eerevisiae a-mating factor signal sequence 
(89 amino acids) contained in pPIC9. 
E. coli strain DH5a [F 080dlacZAM15, recA1, endA1, gyrA96, 
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Fig. 1. Schematic representation f the vectors used for expression of the human ~t-opioid receptor in Pichia pastoris, pPIC9-~MF-HuMOR 
plasmid (A) was constructed by inserting the HUMOR cDNA deleted from its 32 amino-terminal codons (HUMOR A1-32) in frame with the 
sequence coding for the e~-mating factor signal sequence (c~MF) present in the pPIC9 vector, pPICg-STE2-HuMOR (B) contains the HUMOR 
coding region from which the 11 amino-terminal codons (HUMOR A1 11) were replaced by the 18 amino-terminal codons of the STE2 gene. 
The 5' AOX1 and 3' AOX1 (TT) correspond to the promoter and the transcription termination regions of the AOXI gene, respectively. The 
histidinol dehydrogenase (HIS4) and the [~-lactamase (Amp r) genes were used for transformant selection in yeast and E. coli, respectively. 
thi-1, hsdR17(rk , ink+), supE44, relA1, deoR, A(IacZYA-argF)- 
U169] was used for propagation of recombinant plasmids. 
For electrotransformation, a 6.6 kb fragment was isolated from 
pPIC9-STE2-HuMOR and a 6.8 kb fragment from pPIC9-c~MF-Hu- 
MOR by partial digestion of the plasmids with BglII. 
2.2. Yeast transformation and culture 
Two P. pastoris strains (Invitrogen, San Diego) were used in this 
study; GSII5 (his4) and SMDl168 (his4, pep4). Cells were electro- 
transformed with DNA by application of a square wave electric pulse 
of 2.7 kV/cm for 15 ms [18]. For determination f histidine auxotro- 
phy (His+), cells were platted on minimal dextrose (MD) plates 
(0.67% yeast nitrogen base without amino acids, 2% glucose, 
4× 10-5%, biotin) and grown at 30°C for 48-72 h. Controls were 
performed with linearized pPIC9 DNA and with non-transformed 
cells. For determination f the methanol utilization phenotype, single 
colonies of His + transformants were duplicated on MD plates and on 
minimal methanol (MM) plates (same as MD with 0.5% methanol 
instead of glucose) and grown for 2 days at 30°C. 
For receptor expression, His + recombinants with slow methanol 
utilization (Mut ~) were first grown for 48 h at 30°C in repressive 
BMGY medium (1% yeast extract, 2°/,, bacto-peptone, 0.67% yeast 
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nitrogen base without amino acids, 4× 10 5% biotin, 1% glycerol (v/ 
v), 0.1 M phosphate buffer pH 6). After centrifugation (10 min, 
3000×g) cells were re-suspended in the same volume of inducing 
BMMY medium (same as BMGY with glycerol replaced by 0.5% 
methanol) and grown for 40 h at 30°C. 
2.3. Spheroplast preparation 
Spheroplasts were prepared essentially as described (P. pastoris ex- 
pression kit, Invitrogen, San Diego). After induction, cells were har- 
vested by centrifugation (10 min, 3000×g) and sequentially washed 
with water and with 1 M sorbitol, 25 mM EDTA, 50 mM DTT. Cells 
were suspended (10 ~ cells/ml) in 1 M sorbitol, 10 mM citrate buffer 
pH 5.8, 1 mM EDTA, supplemented with 30 /,tg/ml of zymolyase 
(Seikagaku Corp., Japan, l0 s U/g) and were incubated for 30 min 
at 30°C. Spheroplasts were harvested by centrifugation (20 min, 
1000×g) washed with 1 M sorbitol and suspended in 50 mM sodium 
phosphate buffer pH 7.4, 1 mM EDTA, 5% glycerol, 100 mM PMSF. 
2.4. Membranes i olation and radio-ligand binding assays 
All further manipulations were performed on ice. Cells were lysed 
using a Potter-Elvehjem apparatus and the lysate was centrifuged for 
10 min at 10000×g to remove particulate matter. The supernatant 
was centrifuged at 100 000 × g for 35 min. The crude membranes pellet 
was suspended (80 mg/ml) in binding buffer (50 mM Tris-HCl pH 7.5, 
10 mM EDTA), aliquoted and stored at -70°C. Protein concentra- 
tion was measured [19] in the presence of 1% SDS and was between 
4 and 15 mg/ml. 
Saturation binding assays were performed for 1 h at 25°C in 500 ILl 
of binding buffer containing either whole cells (10 s) or isolated mem- 
branes (50 ~tl) and varying concentrations (0.05 to 3 nM) of 
[3H]diprenorphine ([ZH]DPN) (Amersham, spec. act. 41 Ci/mmol). 
Non-specific binding was determined in parallel test tubes in the pre- 
sence of non-labelled iprenorphine (0.05 3 ~tM). Bound and free 
ligand were separated by rapid filtration (Whatman GF/B filters, 
soaked in 0.3% polyethylenimine) and, after 3 washes with l0 mM 
Tris-HCl pH 7.5, filter-bound radioactivity was determined. For dis- 
placement s udies, various concentrations of unlabelled opioid ligand 
and 1 nM [~H]DPN were used. When indicated 100 p,M Gpp(NH)p 
was added to test tubes. Data were analyzed with the INPLOT pro- 
gram (GraphPad software Inc., San Diego, USA) and the results are 
presented as the mean + S.E.M. of 3 independent experiments per- 
formed in duplicate. 
3. Results and discussion 
The methylotrophic yeast P. pastoris has been successfully 
used for the expression of intracellular or secreted proteins [8] 
but there is only one report on the expression of an integral 
membrane protein [9]. The heterologous expression of the 
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Fig. 2. Binding of [3Hldiprenorphine to membranes of Pichia pas- 
toris yeast strain GSI15 transformed with pPIC9-aMF-HuMOR. 
The saturation isotherm and Scatchard plot thereof (inset) are repre- 
sentative of one experiment. 
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Fig, 3. Pharmacological profiles of the ~-opioid receptor expressed 
in Piehia pastoris. Inhibition of [SH]DPN binding (1 nM) to recom- 
binant yeast membranes was performed using agonists (A) DAGO 
(Ill), morphine (zx), DTLET (0), U-50,488 (O) and antagonists (B) 
I3-FNA (•) ,  naloxone (i), NorBNI (• )  and ICI-174,486 (O). 
HUMOR was examined here using integrative plasmids allow- 
ing expression from the endogenous AOX1 promoter which 
upon induction with methanol usually warrants the expression 
of large amounts of methanol oxidase (up to 30% of cell 
proteins) [6]. To increase the possibility of achieving mem- 
brane expression of the receptor, two fusion genes were tested. 
In pPIC9-STE2-HuMOR (Fig. 1A), the hybrid protein com- 
prised the 18 amino-terminal residues of the S. cerevisiae t- 
mating factor receptor which is also a 7 s-helical membrane 
receptor. In pPIC9-cxMF-HuMOR (Fig. 1B), the secretion 
signal of the S. cerevisiae c~-mating factor was used to facil- 
itate membrane translocation of the receptor. In both cases, 
part of the amino-terminus of the receptor was deleted since it 
has been reported that this had no effect on ligand binding 
[20-22]. 
DNA fragments comprising the fusion genes flanked by 5' 
and 3' AOX1 sequences were electro-transformed into the 
GS l l5  (his4) and the protease-deficient SMDl168 (his4, 
pep4) P. pastoris strains and His + transformants were se- 
lected. The Mut ~ phenotype of the transformants was consid- 
ered as indicative of homologous recombination at the A, OX1 
locus but this was not verified further. 
Clones with the His+/MuP phenotype were then tested for 
HUMOR expression. After biomass production in repressive 
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Table 1 
Ligand binding properties of g-opioid receptors expressed in Pich& 
pastoris 
Ligands Ki (nM) 
Antagonists 
non-selective [:~H]DPN (Ka) 0.26 + 0.03 
nMoxone 5 _+ 2 
g-selective 13-FNA 2.0 + 0.5 
g-selective 1CI- 174,486 > 15 000 
~c-selective N orBN I 30 + 3 
Agonists 
g-selective 
8-selective 
~c-selective 
morphine 240 + l0 
morphine+Gpp(N H)p 260 + 15 
DAGO 95 _+ 20 
DAGO+Gpp(NH)p 160 + 10 
DTLET 950 + 95 
U-50,488 2 300 + 100 
Ki values were calculated from competition experiments presented in 
Fig. 3. 
glycerol-containing medium, AOX1 promoter activity was in- 
duced in methanol-containing medium. Intact transformant 
cells were then screened for the presence of opioid binding 
sites by using the antagonist [3H]DPN. Following transforma- 
tion of the GSl l5  strain with pPIC9-c~MF-HuMOR, 35 
[3H]DPN binding clones were obtained out of 40 tested. No 
binding occurred before induction, or on cells transformed 
with the pPIC9 vector. For pPIC9-STE2-HuMOR, no signifi- 
cant binding was detected on intact cells or on membranes 
from 10 His+/Mut ~ clones. 
One of the GS115 clones displaying high and reproducible 
[3H]DPN binding was further characterized. Saturation iso- 
therms and Scatchard analyses thereof indicated a single class 
of specific and saturable binding sites with a Ka of 0.26 + 0.03 
nM and a B ...... of 420 fmol/mg membrane protein (Fig. 2). In 
similar experiments performed on whole cells the Kd was 
0.17+0.02 nM and the receptor density 810 sites/cell (not 
shown). Such receptor densities are in the same range as those 
obtained for expression of Ml -  and M5-muscarinic receptors 
[10,12] in yeast but lower than for 132-adrenergic, D2-dopa- 
minergic and 5HTr, A-serotoninergic receptors [11,13-15]. Uti- 
lization of protease-deficient strains has been suggested to 
increase expression levels of G-protein-coupled receptors in 
S. cerevisiae [11] and P. pastoris [9]. The SMDl168 strain 
was thus tested here but yielded a single positive clone (out 
of 10) with an expression level similar to that of the GS115 
clones. Since it has been shown for oxytocin receptors hetero- 
logously expressed in SJ9 cells that a low membrane choles- 
terol/phospholipid ratio may shift receptors into a low affinity 
state for ligands [23], this possibility was investigated here for 
the g-opioid receptor. However, no low affinity binding was 
detected in competition experiments using concentrations up 
to 1 mM of unlabelled DPN. 
The apparent affinity of [3H]DPN for the g-opioid receptor 
expressed in P. pastoris is similar to that obtained in mamma- 
lian brains (0.1 nM) [24] or cells transfected with the HUMOR 
cDNA (0.2 nM) [16]. The binding properties of the g-opioid 
receptor expressed in P. pastoris membranes were further as- 
sessed by determining the inhibition constants (Ki) of 
[3H]DPN binding by a series of opioid ligands (Fig. 3, Table 
1). These included naloxone, a non-selective antagonist, [3- 
FNA, ICI-174,864 and NorBNI, respectively g-, 8- and ~c- 
selective antagonists as well as morphine, DAGO, DTLET 
and U-50,488 which are two g-, a 8- and a N-selective ago- 
nists, respectively. 
The rank order of potency for antagonist binding, 
[3H]DPN > [5-FNA -> naloxone > NorBNI >> ICI-174,864, 
was typical of ~t-opioid receptors [24-27]. As expected, non- 
selective and ~t-selective antagonists bound to p.-opioid recep- 
tors with K~ values in the low nanomolar ange, whereas the 
~c-selective antagonist NorBNI bound with an affinity in the 
10 100 nM range and the 8-selective antagonist ICI-174,864 
did not readily displace [3H]DPN binding at concentrations a
high as 15 gM. Similarly, the rank order of potency for ago- 
nists binding, DAGO->Morphine>> DTLET > U50.488, was 
the same as that for g-opioid receptors present in mammalian 
tissues or cells [24-26]. The corresponding Ki values (Table 1) 
were, however, low as compared to those of 'native' g-opioid 
receptors. 
It has been reported that the 64 amino-terminal extracellu- 
lar residues of the I.t-opioid receptor could be deleted with 
little effect on ligand binding [20 22]. Our data obtained by 
expressing a wild-type and a truncated (61 amino-terminal 
residues) HUMOR in COS-M6 cells (Emorine L.J., unpub- 
lished) showed that this was indeed true for antagonists but 
that K~ values were increased from 7 to 60 nM for DAGO and 
from 10 to 80 nM for morphine in wild-type and truncated 
receptors, respectively. Additionally, in mammalian cells, 
Gpp(NH)p a non-hydrolysable analogue of GTP, is able to 
shift receptors from a high-affinity to a low-affinity state for 
agonists by uncoupling the receptors and G-proteins [24,28]. 
We showed here that 100 gM Gpp(NH)p had no such effects 
on agonist binding (Table 1), certainly reflecting the lack of 
functional interactions of the HUMOR with host G-proteins. 
Such a situation has already been reported for muscarinic and 
adrenergic receptors expressed in yeast [10-12]. Thus, the de- 
letion of the 32 amino-terminal residues of the receptor as well 
as the lack of coupling to G-proteins may both contribute to 
the low-affinity binding of agonists to ~t-opioid receptors ex- 
pressed in P. pastoris. 
The receptor densities determined in this work are some- 
what lower than those reported for other G-protein-coupled 
receptors expressed in various species of yeast [9,11,13,15]. 
Several studies have documented the utility of signal se- 
quences for the expression of such receptors in yeast. In an 
initial study it was shown that with no modifications of its 
amino-terminus, the human Ml-muscarinic receptor was 
poorly expressed in S. cerevisiae (20 fmol/mg protein) [10]. 
Subsequently, it was suggested that higher expression levels 
could be reached by replacing the amino-terminal part of the 
receptors by the corresponding region of the STE2 gene 
[11,13,15]. Since then, other amino-terminal fusion partners, 
such as the signal sequences for the c~-mating factor [9,12] or 
the acid phosphatase [9] have been successfully used. It should 
be noted, however, that high levels of unmodified opamine 
receptor were obtained in both S. cerevisiae (3 pmol/mg) and 
Schizosaccharomyces pombe (15 pmol/mg) [14]. Together with 
our results, these observations suggest hat the need for a 
signal sequence as well as its nature will have to be empirically 
determined in order to obtain higher expression levels of the 
g-opioid receptor. This could also be achieved by utilizing 
multi-integrative ctors and multi-protease deficient P. pas- 
toris strains instead of the SMDlI68 tested here. 
g-Opioid receptors have been expressed in the P. pastoris 
methylotrophic yeast. Their pharmacological profile is similar 
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to that of receptors naturally occurring in membranes of 
mammalian brains or cells. Expression of 8- and ~-opioid 
receptors which are highly homologous to ~t-opioid receptors 
will certainly follow. These results pave the way for large-scale 
production of/a-opioid receptors, stable isotope labelling [7] 
for NMR or neutron diffraction experiments, and for the 
determination of the conformations of peptidic ligands bound 
to the receptor and eventually of the receptor itself. 
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